FOP News

Clementia Announces Preliminary Results of its Phase 2 Trial in Treatment of FOP

An important announcement from Clementia

The IFOPA is pleased to share this announcement from Clementia Pharmaceuticals: Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with FOP. Read more.

Share

Dr. Fred Kaplan To Receive NORD's Rare Impact Award

The National Organization for Rare Disorders (NORD) named Dr. Fred Kaplan among its 2017 honorees.

Read more.

Share

Regeneron Shares Updates on its Ongoing FOP Research Program

Potentially Promising Treatment for FOP

We are pleased to share a few exciting updates on our ongoing work to help improve the lives of people with FOP. 

Read more Share

Bipartisan Support

21st Century Cures Legislation Signed by President Obama

On December 7, the Senate followed the House of Representative's lead and signed the 21st Century Cures bill which is focused on developing treatments and cures for rare diseases; President Obama signed it on December 13. 

Read more Share

Three new Clementia sites now open for Part B of the Phase 2 Open-label Extension Trial

Approval of 3 New Sites!

The participation of individuals living with FOP in clinical studies and trials is key to FOP drug development efforts. 

Read more Share

Join the IFOPA and Clementia for an Important Webinar

Phase 2 Trial Webinar

We hope you’ll join us Wednesday, Nov. 30, 2016, 11 am to noon Eastern Time, for an important webinar presented by Clementia on the top-line results from the phase 2 trial of palovarotene for treatment of patients with fibrodysplasia ossificans progressiva. 

Read more Share

Opportunity for New Patients to Enroll in Palovarotene Study

Please read Clementia's Clinical Program Announcement: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study. Click here. 

Share

Regeneron's Work in FOP

The International FOP Association is pleased to share the following news from Regeneron Pharmaceuticals

Regeneron is pleased to inform you that anti-Activin A antibody, REGN2477, is now in a clinical trial. 

Read more Share

A Remarkable Record of Service – And An Important Transition

Thank you for your commitment!

Still active in the FOP community, Dr. Pignolo has a accepted a new position.  

Read more Share

Next Step in Clementia's Clinical Program for FOP

Enrollment information and FAQs

The IFOPA is pleased to share the announcement and new FAQs from Clementia Pharmaceuticals regarding the palovarotene clinical trial.

Read more Share

Make a Difference

Donate Connect Fundraise
Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter